Your search for major depressive disorder returned 51 results

The FDA has cleared Nexstim’s NBT system for the treatment of major depressive disorder.

Screening recommended for those aged 12 to 18, however there is insufficient evidence to assess for children aged 11 and younger.

The influence of gut microbiota extends to the brain via neuroinflammation, resulting in symptoms associated with major depressive disorder.

Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.

HIV-infected adults with major depressive disorder have a 30% increased risk for acute myocardial infarction.

The goals of this study were to identify functional connectome fingerprints that predict symptom improvement with any treatment and with specific treatment.

AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.

Researchers conducted a study to evaluate the validity of, and satisfaction with, the Cognition KIT DSST mobile app in patients with major depressive disorder.

More than half of individuals with prior COVID-19 illness have met the criteria for symptoms of major depressive disorder.

The researchers analyzed data from a large randomized noninferiority trial that compared theta-burst stimulation and high-frequency (10 Hz) rTMS delivered to the left dorsolateral prefrontal cortex.

Patients received 40 Hz gamma tACS to provide data on the use of varying stimulation periods.

Investigating whether serial ketamine treatments change functional connectivity between limbic structures and resting-state networks.

There was insufficient evidence to recommend screening in children aged 11 and younger.

The Food and Drug Administration (FDA) has granted Fast Track designation to an investigational intranasal formulation of racemic ketamine for the potential treatment of acute suicidal ideation and behavior in patients with major depressive disorder.

This study addresses the question of whether prescription opioid medications has a potentially causal role in the risk for depression and anxiety disorder.

Convergent abnormalities were observed in secondary analyses across portions of the amygdala, hippocampus, subgenual cingulate cortex, and putamen.

The approval was based on the ASPIRE I and II trials that compared the efficacy and safety of esketamine, an N-methyl-D-aspartate receptor antagonist, to placebo in 449 adults with moderate to severe MDD who had active suicidal ideation and intent.

Sixty percent of patients responded to treatment.

Patients with psychotic depression who experienced an illness relapse while receiving placebo also had a decline in cortical thickness, emphasizing the essential role antipsychotics play in treating disorders where psychosis is present.

For patients with MDD, the change in scores for depression at six weeks does not differ significantly with psilocybin or psilocybin plus escitalopram.

Psilocybin has been shown to have antidepressant properties. With direct comparisons between psilocybin and established treatments for depression lacking, the study researchers looked at psilocybin and escitalopram.

The drug was found to work quickly in patients with clinical major depression.

Most older adults with preexisting MDD showed resilience in the first two months of the COVID-19 pandemic, but they express concerns about the future.

The study provides strong evidence for the utility of resting-state fMRI measures in predicting the development of attentional or mood disorders in children.

Some nutrient supplements may be beneficial as adjunctive treatment for common mental health condition.

Lundbeck announced that the FDA has approved a sNDA for Trintellix to include data regarding improved processing speed.

Changes were more pronounced in depressed volunteers.

Researchers sought to address the possible link between cognitive or mood symptoms and statins.

Transcranial magnetic stimulation (TMS) uses magnetic fields to stimulate nerve cells in the brain.

Escitalopram may be better for the treatment of depression than tDCS.